Home › Trial NCT07722767
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- Trial IDNCT07722767
- StatusNot Yet Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorCullinan Therapeutics Inc.
- Enrollment90
- Start date2026-10-15
- ConditionsAML (Acute Myeloid Leukemia)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.